Concepts (177)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cocaine | 25 | 2016 | 251 | 4.080 |
Why?
|
| Sex Characteristics | 14 | 2013 | 258 | 1.790 |
Why?
|
| Dopamine Uptake Inhibitors | 8 | 2016 | 83 | 1.430 |
Why?
|
| Behavior, Animal | 8 | 2016 | 373 | 1.280 |
Why?
|
| Progesterone | 9 | 2010 | 121 | 1.270 |
Why?
|
| Pain | 6 | 2011 | 290 | 1.120 |
Why?
|
| Cocaine-Related Disorders | 7 | 2013 | 102 | 1.110 |
Why?
|
| Nucleus Accumbens | 4 | 2016 | 100 | 1.040 |
Why?
|
| Estrogens | 5 | 2011 | 203 | 1.040 |
Why?
|
| Rats, Inbred F344 | 21 | 2016 | 258 | 0.980 |
Why?
|
| Rats | 31 | 2016 | 3735 | 0.980 |
Why?
|
| Motor Activity | 8 | 2016 | 437 | 0.910 |
Why?
|
| Testosterone | 4 | 2010 | 211 | 0.870 |
Why?
|
| Estradiol | 5 | 2011 | 268 | 0.830 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 2 | 2016 | 74 | 0.760 |
Why?
|
| Locomotion | 3 | 2016 | 105 | 0.750 |
Why?
|
| Proto-Oncogene Proteins c-fos | 9 | 2016 | 83 | 0.740 |
Why?
|
| Putamen | 3 | 2016 | 16 | 0.650 |
Why?
|
| Caudate Nucleus | 3 | 2016 | 22 | 0.640 |
Why?
|
| Gonadal Steroid Hormones | 3 | 2006 | 55 | 0.640 |
Why?
|
| Animals | 34 | 2016 | 16992 | 0.570 |
Why?
|
| Estrous Cycle | 5 | 2006 | 37 | 0.550 |
Why?
|
| Receptors, Dopamine D1 | 4 | 2009 | 46 | 0.520 |
Why?
|
| Formaldehyde | 4 | 2011 | 31 | 0.520 |
Why?
|
| Pain Threshold | 3 | 2005 | 34 | 0.520 |
Why?
|
| Receptors, Dopamine D2 | 2 | 2010 | 83 | 0.500 |
Why?
|
| Behavior | 3 | 2006 | 35 | 0.500 |
Why?
|
| Ovariectomy | 8 | 2011 | 127 | 0.490 |
Why?
|
| Hyperalgesia | 2 | 2011 | 24 | 0.400 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 4 | 2014 | 52 | 0.400 |
Why?
|
| Dynorphins | 2 | 2003 | 17 | 0.390 |
Why?
|
| Protein Precursors | 2 | 2003 | 59 | 0.390 |
Why?
|
| Corpus Striatum | 3 | 2014 | 121 | 0.380 |
Why?
|
| Brain | 4 | 2013 | 1472 | 0.380 |
Why?
|
| Female | 24 | 2016 | 24698 | 0.370 |
Why?
|
| Gonadal Hormones | 1 | 2012 | 5 | 0.360 |
Why?
|
| Male | 26 | 2016 | 23409 | 0.360 |
Why?
|
| Dopamine and cAMP-Regulated Phosphoprotein 32 | 2 | 2008 | 6 | 0.360 |
Why?
|
| Nociceptors | 2 | 2011 | 30 | 0.350 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 2011 | 41 | 0.340 |
Why?
|
| Tamoxifen | 3 | 2008 | 69 | 0.330 |
Why?
|
| Gene Expression Regulation | 3 | 2005 | 1070 | 0.330 |
Why?
|
| Dizocilpine Maleate | 4 | 2016 | 43 | 0.310 |
Why?
|
| Quinpirole | 1 | 2010 | 18 | 0.310 |
Why?
|
| Dinoprostone | 1 | 2010 | 64 | 0.310 |
Why?
|
| Dopamine Agonists | 1 | 2010 | 34 | 0.310 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2011 | 146 | 0.310 |
Why?
|
| GTP-Binding Proteins | 1 | 2010 | 59 | 0.310 |
Why?
|
| Rats, Sprague-Dawley | 7 | 2011 | 1766 | 0.310 |
Why?
|
| Hormone Replacement Therapy | 2 | 2006 | 49 | 0.300 |
Why?
|
| Sex Factors | 5 | 2016 | 1028 | 0.280 |
Why?
|
| Pregnanolone | 1 | 2008 | 4 | 0.280 |
Why?
|
| Hormone Antagonists | 1 | 2008 | 13 | 0.280 |
Why?
|
| Mifepristone | 1 | 2008 | 34 | 0.270 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 3 | 2016 | 135 | 0.260 |
Why?
|
| Central Nervous System Stimulants | 1 | 2008 | 180 | 0.250 |
Why?
|
| Neurosecretory Systems | 1 | 2006 | 17 | 0.250 |
Why?
|
| Brain Chemistry | 1 | 2006 | 141 | 0.240 |
Why?
|
| Dose-Response Relationship, Drug | 6 | 2008 | 1124 | 0.240 |
Why?
|
| Reward | 2 | 2004 | 112 | 0.230 |
Why?
|
| Conditioning, Operant | 2 | 2013 | 90 | 0.230 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2005 | 137 | 0.230 |
Why?
|
| Ovary | 1 | 2005 | 113 | 0.220 |
Why?
|
| Signal Transduction | 4 | 2016 | 2157 | 0.210 |
Why?
|
| Biogenic Monoamines | 1 | 2004 | 32 | 0.210 |
Why?
|
| Endocrine System | 1 | 2003 | 12 | 0.210 |
Why?
|
| Inflammation | 2 | 2010 | 758 | 0.210 |
Why?
|
| Corticosterone | 4 | 2010 | 90 | 0.210 |
Why?
|
| Anesthetics, Local | 1 | 2003 | 20 | 0.200 |
Why?
|
| Models, Animal | 3 | 2012 | 151 | 0.200 |
Why?
|
| Astrocytes | 2 | 2002 | 244 | 0.200 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2005 | 187 | 0.200 |
Why?
|
| Lymphokines | 1 | 2002 | 18 | 0.190 |
Why?
|
| Growth Inhibitors | 1 | 2002 | 29 | 0.190 |
Why?
|
| Neostriatum | 1 | 2002 | 28 | 0.190 |
Why?
|
| Pain Measurement | 3 | 2010 | 183 | 0.180 |
Why?
|
| Disease Models, Animal | 5 | 2011 | 1596 | 0.180 |
Why?
|
| Excitatory Amino Acid Antagonists | 5 | 2016 | 92 | 0.180 |
Why?
|
| Phosphorylation | 6 | 2014 | 986 | 0.180 |
Why?
|
| Interleukin-6 | 1 | 2002 | 165 | 0.180 |
Why?
|
| Glioma | 1 | 2002 | 96 | 0.170 |
Why?
|
| Interferon-gamma | 1 | 2002 | 269 | 0.170 |
Why?
|
| Trans-Activators | 1 | 2002 | 192 | 0.170 |
Why?
|
| Blotting, Western | 5 | 2013 | 883 | 0.170 |
Why?
|
| Hypothalamo-Hypophyseal System | 2 | 2011 | 55 | 0.150 |
Why?
|
| Drug Administration Schedule | 3 | 2003 | 153 | 0.150 |
Why?
|
| DNA-Binding Proteins | 1 | 2002 | 561 | 0.150 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 4 | 2014 | 98 | 0.130 |
Why?
|
| Dopamine Antagonists | 3 | 2008 | 48 | 0.130 |
Why?
|
| Cyclin-Dependent Kinase 5 | 1 | 2016 | 9 | 0.130 |
Why?
|
| Drug Tolerance | 1 | 2016 | 26 | 0.130 |
Why?
|
| Phosphotransferases | 1 | 2016 | 36 | 0.120 |
Why?
|
| Conditioning, Classical | 1 | 2016 | 67 | 0.120 |
Why?
|
| Salicylamides | 2 | 2005 | 13 | 0.120 |
Why?
|
| Menstrual Cycle | 2 | 2006 | 36 | 0.120 |
Why?
|
| Analysis of Variance | 2 | 2008 | 575 | 0.110 |
Why?
|
| Down-Regulation | 1 | 2016 | 456 | 0.110 |
Why?
|
| Drug Interactions | 2 | 2005 | 150 | 0.110 |
Why?
|
| RNA, Messenger | 3 | 2003 | 1271 | 0.100 |
Why?
|
| Antineoplastic Agents | 1 | 2002 | 1019 | 0.100 |
Why?
|
| Time Factors | 4 | 2016 | 1857 | 0.100 |
Why?
|
| Irritants | 1 | 2011 | 8 | 0.090 |
Why?
|
| Carrageenan | 1 | 2011 | 16 | 0.090 |
Why?
|
| Radioimmunoassay | 2 | 2008 | 70 | 0.080 |
Why?
|
| Pituitary-Adrenal System | 1 | 2011 | 41 | 0.080 |
Why?
|
| Cerebral Cortex | 2 | 2002 | 306 | 0.080 |
Why?
|
| Drug Synergism | 1 | 2011 | 195 | 0.080 |
Why?
|
| Guanosine 5'-O-(3-Thiotriphosphate) | 1 | 2010 | 6 | 0.080 |
Why?
|
| Autoradiography | 1 | 2010 | 37 | 0.080 |
Why?
|
| Cyclooxygenase 1 | 1 | 2010 | 13 | 0.080 |
Why?
|
| Binding, Competitive | 1 | 2010 | 109 | 0.080 |
Why?
|
| Enzyme Activation | 1 | 2011 | 462 | 0.080 |
Why?
|
| Cyclooxygenase 2 | 1 | 2010 | 107 | 0.080 |
Why?
|
| Estrogen Antagonists | 2 | 2006 | 30 | 0.070 |
Why?
|
| Spinal Cord | 1 | 2010 | 114 | 0.070 |
Why?
|
| Calcineurin | 1 | 2008 | 23 | 0.070 |
Why?
|
| Injections, Intraperitoneal | 1 | 2008 | 60 | 0.070 |
Why?
|
| Enzyme Inhibitors | 1 | 2011 | 458 | 0.070 |
Why?
|
| Models, Neurological | 1 | 2009 | 136 | 0.070 |
Why?
|
| Protein Phosphatase 1 | 1 | 2008 | 70 | 0.070 |
Why?
|
| Castration | 1 | 2008 | 34 | 0.070 |
Why?
|
| Stereotyped Behavior | 1 | 2008 | 23 | 0.070 |
Why?
|
| Prefrontal Cortex | 1 | 2010 | 164 | 0.070 |
Why?
|
| Receptors, Estrogen | 2 | 2006 | 183 | 0.070 |
Why?
|
| Receptors, Progesterone | 1 | 2008 | 92 | 0.070 |
Why?
|
| Dopamine | 1 | 2008 | 275 | 0.060 |
Why?
|
| Humans | 5 | 2012 | 43102 | 0.060 |
Why?
|
| Infusion Pumps, Implantable | 1 | 2005 | 4 | 0.060 |
Why?
|
| Silicones | 1 | 2005 | 7 | 0.060 |
Why?
|
| Metabolic Clearance Rate | 1 | 2005 | 30 | 0.060 |
Why?
|
| Dimethylpolysiloxanes | 1 | 2005 | 16 | 0.060 |
Why?
|
| Membrane Proteins | 1 | 2010 | 561 | 0.060 |
Why?
|
| Capsules | 1 | 2005 | 28 | 0.060 |
Why?
|
| Analgesia | 1 | 2005 | 11 | 0.060 |
Why?
|
| Enzyme Induction | 1 | 2005 | 52 | 0.060 |
Why?
|
| Membranes, Artificial | 1 | 2005 | 33 | 0.060 |
Why?
|
| Menstruation | 1 | 2005 | 11 | 0.060 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2005 | 54 | 0.060 |
Why?
|
| Statistics, Nonparametric | 1 | 2005 | 113 | 0.060 |
Why?
|
| Benzazepines | 1 | 2005 | 33 | 0.060 |
Why?
|
| Peripheral Nerves | 1 | 2005 | 14 | 0.060 |
Why?
|
| Neurons, Afferent | 1 | 2005 | 44 | 0.060 |
Why?
|
| Morphine | 1 | 2005 | 69 | 0.060 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2005 | 127 | 0.060 |
Why?
|
| Orchiectomy | 1 | 2004 | 37 | 0.060 |
Why?
|
| Up-Regulation | 2 | 2008 | 536 | 0.050 |
Why?
|
| Clinical Trials as Topic | 1 | 2005 | 259 | 0.050 |
Why?
|
| Adrenalectomy | 1 | 2003 | 23 | 0.050 |
Why?
|
| Leukemia Inhibitory Factor | 1 | 2002 | 6 | 0.050 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2006 | 734 | 0.050 |
Why?
|
| STAT1 Transcription Factor | 1 | 2002 | 34 | 0.050 |
Why?
|
| Receptors, Opioid, mu | 1 | 2002 | 52 | 0.050 |
Why?
|
| Chronic Disease | 1 | 2005 | 549 | 0.050 |
Why?
|
| STAT3 Transcription Factor | 1 | 2002 | 102 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 1 | 2002 | 508 | 0.040 |
Why?
|
| RNA | 1 | 2002 | 266 | 0.040 |
Why?
|
| Gene Expression | 1 | 2002 | 701 | 0.040 |
Why?
|
| Sirtuin 2 | 1 | 2016 | 3 | 0.030 |
Why?
|
| CREB-Binding Protein | 1 | 2016 | 13 | 0.030 |
Why?
|
| Sirtuin 1 | 1 | 2016 | 34 | 0.030 |
Why?
|
| Globus Pallidus | 1 | 2016 | 21 | 0.030 |
Why?
|
| Mice | 1 | 2004 | 6644 | 0.020 |
Why?
|
| Excitatory Amino Acid Agonists | 1 | 2009 | 43 | 0.020 |
Why?
|
| N-Methylaspartate | 1 | 2009 | 59 | 0.020 |
Why?
|
| Immunoprecipitation | 1 | 2009 | 127 | 0.020 |
Why?
|
| Tubulin | 1 | 2009 | 96 | 0.020 |
Why?
|
| Dual Specificity Phosphatase 1 | 1 | 2008 | 8 | 0.020 |
Why?
|
| Genes, Immediate-Early | 1 | 2008 | 10 | 0.020 |
Why?
|
| Peripheral Nervous System | 1 | 2006 | 14 | 0.020 |
Why?
|
| Vagina | 1 | 2006 | 89 | 0.020 |
Why?
|
| Central Nervous System | 1 | 2006 | 152 | 0.010 |
Why?
|
| Nerve Tissue Proteins | 1 | 2007 | 386 | 0.010 |
Why?
|
| Glial Fibrillary Acidic Protein | 1 | 2002 | 75 | 0.010 |
Why?
|
| Animals, Newborn | 1 | 2002 | 352 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2002 | 934 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2002 | 638 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2002 | 1621 | 0.010 |
Why?
|
Quinones-Jenab's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(177)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(1)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People who are also in this person's primary department.
Explore
_